REATA PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Reata Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2023.
  • Reata Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was $193M.
  • Reata Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2023 was -$87.6M, a 71.2% increase year-over-year.
  • Reata Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$312M, a 4.88% decline from 2021.
  • Reata Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$297M, a 20% decline from 2020.
  • Reata Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2020 was -$248M, a 14.6% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$87.6M $193M +$267M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$354M -$116M -$42.3M -57.3% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-10
Q4 2022 -$312M -$85.5M -$117K -0.14% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-24
Q3 2022 -$312M -$79M -$7.16M -9.96% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-08
Q2 2022 -$305M -$73.6M -$855K -1.18% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$304M -$73.8M -$6.39M -9.47% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$297M -$85.4M -$19.6M -29.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-24
Q3 2021 -$278M -$71.8M -$6.39M -9.76% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$271M -$72.7M -$5.12M -7.58% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$266M -$67.5M -$18.5M -37.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$248M -$65.8M +$121M +64.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$369M -$65.5M -$25.8M -64.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$343M -$67.6M -$33.2M -96.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$310M -$48.9M -$19.8M -67.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$290M -$187M -$161M -631% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$129M -$39.7M -$8.86M -28.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$120M -$34.4M -$6.17M -21.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$114M -$29.2M -$33.2M -814% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$80.5M -$25.6M -$8.91M -53.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-19
Q3 2018 -$71.6M -$30.8M -$18.5M -151% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-19
Q2 2018 -$53.1M -$28.2M -$16.6M -143% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-19
Q1 2018 -$36.5M $4.08M +$11.2M Jan 1, 2018 Mar 31, 2018 10-K 2020-02-19
Q4 2017 -$47.7M -$16.7M -$12.5M -303% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$35.1M -$12.3M -$11.4M -1272% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$23.7M -$11.6M -$10.7M -1138% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$13.1M -$7.1M -$6.84M -2651% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$6.23M -$4.14M -$2.39M -137% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-02
Q3 2016 -$3.84M -$897K -$1.53M -242% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-02
Q2 2016 -$2.31M -$936K +$759K +44.8% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-02
Q1 2016 -$3.07M -$258K -$1.62M -119% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-02
Q4 2015 -$1.45M -$1.75M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-03
Q3 2015 $633K Jul 1, 2015 Sep 30, 2015 10-K 2017-03-03
Q2 2015 -$1.7M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-03
Q1 2015 $1.36M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.